Global Registry
A4D-Ab
Lirilumab
A4DAB156
|
Phase-II
Target
KIRD2
Isotype / Subclass
G4 / None
Company
Novo Nordisk
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Innate Pharma
National Cancer Institute (USA)
Ono Pharmaceutical
PrECOG
University of Texas M. D. Anderson Cancer Center
Clinical Status
Phase-II
Format
Whole mAb
Synonyms
BMS-986015
BMS986015
BMS 986015
IPH-21
IPH21
IPH 21
IPH-2101
IPH2101
IPH 2101
IPH-2102
IPH 2102
IPH2102
NN 1975
NN1975
NN-1975
ONO-4483
ONO4483
ONO 4483
pH Formulation
—
IMGT
PubChem (160693186)
PubChem (318164829)
PubChem (347911236)
PubChem (381126010)
PubChem (472405237)
PubChem (472435534)
PubChem (472440389)
PubChem (481155331)
PubChem (498156073)
Thera-SAbDab
YAbS
Avg A4D Score
-0.5958
Score Range
-0.6
Structures
1
Show Structure Profiles
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity
Associated Structural Profiles
Level 2
Export CSV
Column Filters
Min Seq. Identity (%)
0
Min Avg A4D Score
-5.0
Max Avg A4D Score
2.0
Min pH (min agg. prop.)
0.0
Max pH (max agg. prop.)
14.0
Reset Filters
Structure ID
Source PDB
Seq. Identity
Avg. A4D Score
pH (Min Agg.)
pH (Max Agg.)
Score CDR
Score non-CDR
A4DAB156_8tui_H_L
8tui
100%
-0.5958
6.5
4.0
0.0143
-0.6751